Developing a germline prostate cancer risk test incorporating rare and common variants, to inform clinical decisions: a route to precision oncology. - Wakerell S; Karlsson Q; Merson S; Rageevakumar R; Saunders E; Burns D; Brook MN; Dadaev T; Page EC; Thomas S; Taylor N; Pope J; et al. (Genome medicine, 2026)